ReviewGlobal spine journal2017
Corticosteroid Treatment for Metastatic Spinal Cord Compression: A Review.
Review in Global spine journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 38 citations in OpenAlex.
- Evidence-based management of metastatic spinal cord compression (MSCC): expert recommendations for standardizing care in Spain.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Metastatic Colorectal Cancer Presenting as Spinal Cord Compression and Mimicking Tuberculosis.Cureus · 2025Article
- Adrenergic receptors blockade alleviates dexamethasone-induced neurotoxicity in adult male Wistar rats: Distinct effects on β-arrestin2 expression and molecular markers of neural injury.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2024Article
- Intramedullary spinal cord metastasis treated with prophylactic laminoplasty prior to radiation to the spinal cord: a case report.Journal of spine surgery (Hong Kong) · 2023Article
- Vertebral Primary Bone Lesions: Review of Management Options.Current oncology (Toronto, Ont.) · 2023Review
- Review
- Do Patients Benefit from a Trial of Corticosteroids at the End of Life?Current treatment options in oncology · 2022Review
- Spontaneous Spinal Epidural Hematoma: A Case of a Benign Presentation and Emergency Department Management.Cureus · 2022Article
- Steroids in the Management of Preoperative Neurological Deficits in Metastatic Spine Disease: Results From the EPOSO Study.Neurospine · 2022Article
- Clinical Therapy of Metastatic Spinal Tumors.Frontiers in surgery · 2021Review
- Multidisciplinary management of metastatic spine disease: initial symptom-directed management.Neuro-oncology practice · 2020Article
- Adapting palliative radiation therapy for bone metastases during the Covid-19 pandemic: GEMO position paper.Journal of bone oncology · 2020Article
- Acute Lymphoblastic Leukemia Presenting Initially as Spinal Cord Compression: When Chemotherapy Alone Is Enough.Case reports in medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
STUDY
designNarrative review.
objectiveMetastatic spinal cord compression (MSCC) is a very frequent complication among cancer patients. Presenting commonly as nocturnal back pain, MSCC typically progresses to lower extremity paresis, loss of ambulatory capabilities, and paraplegia. In addition to standard treatment modalities, corticosteroid administration has been utilized in preclinical and clinical settings as adjunctive therapy to reduce local spinal cord edema and improve clinical symptoms. This article serves as a review of existing literature regarding corticosteroid management of MSCC and seeks to provide potential avenues of research on the topic.
methodsA literature search was performed using PubMed in order to consolidate existing information regarding dexamethasone treatment of MSCC. Of all search results, 7 articles are reviewed, establishing the current understanding of metastatic spine disease and dexamethasone treatment in both animal models and in clinical trials.
resultsTreatment with high-dose corticosteroids is associated with an increased rate of potentially serious systemic side effects. For this reason, definitive guidelines for the use of dexamethasone in the management of MSCC are unavailable.
conclusionsIt is still unclear what role dexamethasone plays in the treatment of MSCC. It is evident that new, more localizable therapies may provide more acceptable treatment strategies using corticosteroids. Looking forward, the potential for more targeted, localized application of the steroid through the use of nanotechnology would decrease the incidence of adverse effects while maintaining the drug's efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.